Literature DB >> 31486044

Use of Liquid Patient Ascites Fluids as a Preclinical Model for Oncolytic Virus Activity.

Eleanor M Scott1, Sally Frost1, Hena Khalique1, Joshua D Freedman1, Len W Seymour1, Janet Lei-Rossmann2.   

Abstract

The translational success of oncolytic virotherapies would benefit from the widespread use of clinically relevant ex vivo models. Malignant ascites, an accumulation of fluid in the peritoneum due to disseminated cancer, recapitulates many features of the tumor microenvironment, making it a valuable model for studying oncolytic virus activity. Here, we describe a method for the separation and storage of cellular and acellular components of malignant ascites, followed by flow cytometric characterization of the cellular fraction. We then outline a simple experiment using whole ascites to assess the activity of a bispecific T cell engager (BiTE)-expressing oncolytic adenovirus.

Entities:  

Keywords:  Ascites; Ex vivo model; Flow cytometry; Liquid biopsies; Oncolytic virus

Year:  2020        PMID: 31486044     DOI: 10.1007/978-1-4939-9794-7_17

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

Review 1.  Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus.

Authors:  Peter Kok-Ting Wan; Anderson J Ryan; Leonard W Seymour
Journal:  Mol Ther       Date:  2021-04-19       Impact factor: 11.454

Review 2.  Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.

Authors:  Johannes P W Heidbuechel; Christine E Engeland
Journal:  J Hematol Oncol       Date:  2021-04-16       Impact factor: 17.388

3.  Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.

Authors:  Hena Khalique; Richard Baugh; Arthur Dyer; Eleanor M Scott; Sally Frost; Sarah Larkin; Janet Lei-Rossmann; Leonard W Seymour
Journal:  J Immunother Cancer       Date:  2021-03       Impact factor: 13.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.